Please ensure Javascript is enabled for purposes of website accessibility

Trump Administration Considers Reimbursing Hospitals to Treat Uninsured Coronavirus Patients

By Mark Prvulovic - Mar 3, 2020 at 5:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coronavirus patients without insurance could have their medical bills covered by the government.

The Trump administration is considering whether to invoke the National Disaster Medical System reimbursement program, which would cover hospital and medical costs to treat uninsured patients infected with the novel coronavirus, according to the Wall Street Journal. In disaster situations, such as hurricanes, the program reimburses medical groups for treating uninsured patients in hard-hit zones, covering 110% of the standard Medicare rates.

Robert Kadlec, a Department of Health and Human Services official, said at a congressional hearing that the Trump administration is considering using the program as a means of helping the millions of Americans without health insurance. Around 27.5 million Americans lacked healthcare coverage at some point this year, which is around 8.5% of the country's total population.

A doctor holding his hand out with the word medicare above.

Image source: Getty Images

The latest COVID-19 details

Over the past week, the number of COVID-19 deaths in the U.S. grew to nine, while the number of confirmed cases in the country reached 118. Although the World Health Organization (WHO) has refrained from classifying the COVID-19 outbreak as a pandemic, the head of WHO did warn that the world is entering "uncharted territory" as they try to fight the virus.

There are a couple of possible COVID-19 drugs in clinical testing right now, Gilead Sciences' (GILD -1.07%) former Ebola treatment remdesivir and Moderna's (MRNA 0.03%) mRNA-based vaccine candidate. But it will likely be quite some time before either medicine is available to the public.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$61.81 (-1.07%) $0.67
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$142.85 (0.03%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.